Tarek Samad

Digital

pharmaphorum podcast Episode 236, Tarek Samad, Lundbeck

An AI supercomputer and discovering next-gen brain disorder ...

Tarek Samad, Lundbeck’s senior vice president and head of research, discusses AI – specifically, Lundbeck’s agreement with the DCAI to operate Gefion.

News

Chiesi signs $1.9bn deal to buy KalVista and its HAE drug

Chiesi has boosted its rare disease business with an agreement to buy KalVista and Ekterly, its oral drug for treating attacks in rare disease HAE.

/themes/custom/pharmaphorum_theme/library/img/article-label-image/ondemand.png

Sales & Marketing

Using AI-driven synthetic personas to take your insights fur...

As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.

Editor's Picks